NxStage Medical, Inc. (NASDAQ:NXTM) has been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and nine have issued a hold rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $30.00.

Several analysts recently commented on NXTM shares. Leerink Swann downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $28.00 to $30.00 in a report on Tuesday, August 22nd. Zacks Investment Research cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. William Blair cut shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, August 7th. Northland Securities reiterated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research note on Wednesday, November 8th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research note on Tuesday, October 17th.

COPYRIGHT VIOLATION NOTICE: “NxStage Medical, Inc. (NXTM) Given Consensus Recommendation of “Hold” by Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/13/nxstage-medical-inc-nxtm-given-consensus-recommendation-of-hold-by-brokerages-2.html.

Shares of NxStage Medical (NXTM) traded down $0.02 during mid-day trading on Monday, hitting $25.79. 902,000 shares of the company traded hands, compared to its average volume of 636,527. NxStage Medical has a 1-year low of $20.45 and a 1-year high of $30.80.

In other news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $29.21, for a total value of $102,235.00. Following the completion of the transaction, the senior vice president now directly owns 16,270 shares in the company, valued at approximately $475,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Matthew W. Towse sold 4,300 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $27.27, for a total transaction of $117,261.00. Following the completion of the transaction, the senior vice president now owns 28,721 shares of the company’s stock, valued at $783,221.67. The disclosure for this sale can be found here. Insiders sold a total of 17,600 shares of company stock valued at $496,902 over the last 90 days. Corporate insiders own 4.70% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC increased its position in NxStage Medical by 31.8% during the 2nd quarter. FMR LLC now owns 9,860,278 shares of the medical device company’s stock worth $247,197,000 after purchasing an additional 2,378,077 shares in the last quarter. Vanguard Group Inc. increased its position in NxStage Medical by 8.5% during the 1st quarter. Vanguard Group Inc. now owns 5,273,762 shares of the medical device company’s stock worth $141,495,000 after purchasing an additional 412,233 shares in the last quarter. BlackRock Inc. increased its position in NxStage Medical by 38,360.4% during the 1st quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock worth $118,408,000 after purchasing an additional 4,401,851 shares in the last quarter. Eagle Asset Management Inc. increased its position in NxStage Medical by 26.6% during the 2nd quarter. Eagle Asset Management Inc. now owns 2,573,603 shares of the medical device company’s stock worth $64,520,000 after purchasing an additional 540,103 shares in the last quarter. Finally, William Blair Investment Management LLC increased its position in NxStage Medical by 491.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,959,318 shares of the medical device company’s stock worth $49,120,000 after purchasing an additional 1,628,114 shares in the last quarter. Institutional investors and hedge funds own 92.31% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.